日本内科学会

The current issues and future perspective of artificial intelligence for developing new treatment strategy in non-small cell lung cancer: harmonization of molecular cancer biology and artificial intelligence Reviewed International journal

Tanaka Ichidai, Furukawa Taiki, Morise Masahiro

CANCER CELL INTERNATIONAL   Vol. 21 ( 1 ) page： 454   2021.8

Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma. Reviewed International journal

Nakagawa K, Kijima T, Okada M, Morise M, Kato M, Hirano K, Fujimoto N, Takenoyama M, Yokouchi H, Ohe Y, Hida T, Aoe K, Kishimoto T, Hirokawa M, Matsuki H, Kaneko Y, Yamada T, Morimoto C, Takeda M

JTO clinical and research reports   Vol. 2 ( 6 ) page： 100178   2021.6

Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With <i>EGFR</i> Mutations. Reviewed International journal

Ninomiya K, Teraoka S, Zenke Y, Kenmotsu H, Nakamura Y, Okuma Y, Tamiya A, Nosaki K, Morise M, Aokage K, Oya Y, Kozuki T, Sakamoto T, Tanaka K, Tanaka H, Tanizaki J, Miura S, Mizutani H, Miyauchi E, Yamaguchi O, Ebi N, Goto Y, Sasaki T, Daga H, Morita S, Yamanaka T, Amano S, Hasegawa K, Imamura CK, Suzuki K, Nakajima K, Nishimoto H, Oizumi S, Hida T, Hotta K, Takiguchi Y

JTO clinical and research reports   Vol. 2 ( 1 ) page： 100107   2021.1

Comparative study of anti-SARS-CoV-2 antibody testing: Relationship between target antigen and immunoglobulin isotype Reviewed International journal

KIM Jeong Hui, KIKUCHI Ryosuke, SUZUKI Atsuo, WATARAI Rika, YOKOYAMA Satoru, MORISE Masahiro, YAGI Tetsuya, MATSUSHITA Tadashi

Japanese Journal of Medical Technology   Vol. 69 ( 4 ) page： 554 - 561   2020.10

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC Reviewed International coauthorship International journal

Herbst Roy S., Giaccone Giuseppe, de Marinis Filippo, Reinmuth Niels, Vergnenegre Alain, Barrios Carlos H., Morise Masahiro, Felip Enriqueta, Andric Zoran, Geater Sarayut, Ozguroglu Mustafa, Zou Wei, Sandler Alan, Enquist Ida, Komatsubara Kimberly, Deng Yu, Kuriki Hiroshi, Wen Xiaohui, McCleland Mark, Mocci Simonetta, Jassem Jacek, Spigel David R.

NEW ENGLAND JOURNAL OF MEDICINE   Vol. 383 ( 14 ) page： 1328 - 1339   2020.10

Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy Reviewed International journal

Sugawara Shunichi, Inui Naoki, Kanehara Masashi, Morise Masahiro, Yoshimori Kozo, Kumagai Toru, Fukui Tomoya, Minato Koichi, Iwashima Akira, Takeda Yuichiro, Kubota Kaoru, Saeki Toshiaki, Tamura Tomohide

CANCER   Vol. 125 ( 22 ) page： 4076 - 4083   2019.11

The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. Reviewed International journal

Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y, Kozuki T, Miura S, Sasaki T, Tamiya A, Teraoka S, Tsubata Y, Yoshioka H, Hattori Y, Imamura CK, Katsuya Y, Matsui R, Minegishi Y, Mizugaki H, Nosaki K, Okuma Y, Sakamoto S, Sone T, Tanaka K, Umemura S, Yamanaka T, Amano S, Hasegawa K, Morita S, Nakajima K, Maemondo M, Seto T, Yamamoto N

International journal of clinical oncology   Vol. 24 ( 7 ) page： 731 - 770   2019.7

12. Clinical Practice of Lung Cancer in Elderly Patients International journal

Hasegawa Yoshinori, Morise Masahiro

Nihon Naika Gakkai Zasshi   Vol. 106 ( 9 ) page： 1986 - 1990   2017.9

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis Reviewed International journal

Gen Soei, Tanaka Ichidai, Morise Masahiro, Koyama Junji, Kodama Yuta, Matsui Akira, Miyazawa Ayako, Hase Tetsunari, Hibino Yoshitaka, Yokoyama Toshihiko, Kimura Tomoki, Yoshida Norio, Sato Mitsuo, Hashimoto Naozumi

BMC CANCER   Vol. 22 ( 1 ) page： 654   2022.6

Amelanotic Malignant Melanoma with a <i>BRAF V600E</i> Mutation Mimicking Primary Lung Cancer Reviewed International journal

Matsuzawa Reiko, Morise Masahiro, Tanaka Ichidai, Hayai Shunsaku, Tamiya Yutaro, Koyama Junji, Hase Tetsunari, Wakahara Keiko, Deoksu Kim, Shimoyama Yoshie, Hashimoto Naozumi

Internal Medicine   Vol. 61 ( 5 ) page： 703 - 708   2022.5

Resistance to mutant KRASV12-induced senescence in an hTERT/Cdk4-immortalized normal human bronchial epithelial cell line Reviewed International coauthorship

Muraki N, Yamada M, Doki H, Nakai R, Komeda K, Goto D, Kawabe N, Matsuoka K, Matsushima M, Kawabe T, Tanaka I, Morise M, Shay JW, Minna JD, Sato M.

Exp Cell Res   Vol. 414 ( 1 ) page： 113053   2022.5

Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE) Reviewed International journal

Hata Akito, Shiraishi Yoshimasa, Inui Naoki, Okada Morihito, Morise Masahiro, Akiyoshi Kohei, Takeda Masayuki, Watanabe Yasutaka, Sugawara Shunichi, Shinagawa Naofumi, Kubota Kaoru, Saeki Toshiaki, Tamura Tomohide

ONCOLOGY AND THERAPY     2022.3

INSIGHT 2: a Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance Reviewed International coauthorship International journal

Smit Egbert F., Dooms Christophe, Raskin Jo, Nadal Ernest, Tho Lye M., Le Xiuning, Mazieres Julien, Hin How S., Morise Masahire, Zhu Viola W., Tan Daniel, Holmberg Kristina H., Ellers-Lenz Barbara, Adrian Svenja, Brutlach Sabine, Schumacher Karl M., Karachaliou Niki, Wu Yi-Long

FUTURE ONCOLOGY   Vol. 18 ( 9 ) page： 1039 - 1054   2022.3

Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations Reviewed International journal

Tanaka Ichidai, Morise Masahiro

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES   Vol. 23 ( 1 )   2022.1

A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer Reviewed International journal

Yasuda Hiroyuki, Ichihara Eiki, Sakakibara-Konishi Jun, Zenke Yoshitaka, Takeuchi Shinji, Morise Masahiro, Hotta Katsuyuki, Sato Mineyoshi, Matsumoto Shingo, Tanimoto Azusa, Matsuzawa Reiko, Kiura Katuyuki, Takashima Yuta, Yano Seiji, Koyama Junji, Fukushima Takahiro, Hamamoto Junko, Terai Hideki, Ikemura Shinnosuke, Takemura Ryo, Goto Koichi, Soejima Kenzo

LUNG CANCER   Vol. 162   page： 140 - 146   2021.12

Oxytocin receptor is a promising therapeutic target of malignant mesothelioma Reviewed International journal

Kodama Yuta, Tanaka Ichidai, Sato Tatsuhiro, Hori Kazumi, Gen Soei, Morise Masahiro, Matsubara Daisuke, Sato Mitsuo, Sekido Yoshitaka, Hashimoto Naozumi

CANCER SCIENCE   Vol. 112 ( 9 ) page： 3520 - 3532   2021.9

A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903 Reviewed International journal

Ito K., Morise M., Wakuda K., Hataji O., Shimokawaji T., Takahashi K., Furuya N., Takeyama Y., Goto Y., Abe T., Kato T., Ozone S., Ikeda S., Kogure Y., Yokoyama T., Kimura M., Yoshioka H., Murotani K., Kondo M., Saka H.

ESMO OPEN   Vol. 6 ( 3 )   2021.6

A phase III, randomized, double-blind, multicenter, active control study of fosnetupitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving cisplatin-based highly emetogenic chemotherapy (HEC): CONSOLE. Reviewed International journal

Shiraishi, Y; Hata, A; Inui, N; Okada, M; Morise, M; Akiyoshi, K; Takeda, M; Watanabe, Y; Sugawara, S; Shinagawa, N; Kubota, K; Saeki, T; Tamura, T

JOURNAL OF CLINICAL ONCOLOGY   Vol. 39 ( 15 )   2021.5

IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chemotherapy as First-Line Treatment in PD-L1-Selected NSCLC Reviewed International coauthorship International journal

Herbst R., De Marinis F., Giaccone G., Vergnenegre A., Barrios C., Morise M., Felip E., Oprean C., Kim Y., Andric Z., Mocci S., Enquist I., Komatsubara K., Mccleland M., Deng Y., Kuriki H., Villalobos M., Phan S., Spigel D., Jassem J.

JOURNAL OF THORACIC ONCOLOGY   Vol. 16 ( 3 ) page： S224 - S225   2021.3

Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study Reviewed International coauthorship International journal

Seto Takashi, Hayashi Hidetoshi, Satouchi Miyako, Goto Yasushi, Niho Seiji, Nogami Naoyuki, Hida Toyoaki, Takahashi Toshiaki, Sakakibara-Konishi Jun, Morise Masahiro, Nagasawa Takashi, Suzuki Mie, Ohkura Masayuki, Fukuhara Kei, Thurm Holger, Peltz Gerson, Nishio Makoto

CANCER SCIENCE   Vol. 111 ( 10 ) page： 3726 - 3738   2020.10

Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study Reviewed International journal

Nakano Takashi, Kuribayashi Kozo, Kondo Masashi, Morise Masahiro, Tada Yuji, Hirano Katsuya, Hayashi Morihiko, Tanaka Misa, Hirabayashi Masataka

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY     2020.9

Clinical burden of immune checkpoint inhibitor-induced pneumonitis Reviewed International journal

Sakamoto Koji, Fukihara Jun, Morise Masahiro, Hashimoto Naozumi

RESPIRATORY INVESTIGATION   Vol. 58 ( 5 ) page： 305 - 319   2020.9

Primary Prophylaxis Indication for Docetaxel Induced Febrile Neutropenia in Elderly Patients with Non-Small Cell Lung Cancer Reviewed International journal

Matsui Akira, Morise Masahiro, Tanaka Ichidai, Ozone Sachiko, Matsuzawa Reiko, Koyama Junji, Hase Tetsunari, Hashimoto Naozumi, Sato Mitsuo, Hasegawa Yoshinori

CANCER INVESTIGATION   Vol. 38 ( 7 ) page： 424 - 430   2020.8

Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer Patients With EGFR Mutation Reviewed International journal

Tanaka Ichidai, Morise Masahiro, Miyazawa Ayako, Kodama Yuta, Tamiya Yutaro, Gen Soei, Matsui Akira, Hase Tetsunari, Hashimoto Naozumi, Sato Mitsuo, Hasegawa Yoshinori

CLINICAL LUNG CANCER   Vol. 21 ( 3 ) page： 273 - +   2020.5

Reply to "Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With NoneSmall-Cell Lung Cancer Who Received Programmed Death-1 Inhibitors" Reviewed International journal

Fukihara Jun, Sakamoto Koji, Koyama Junji, Ito Takayasu, Iwano Shingo, Morise Masahiro, Ogawa Masahiro, Kondoh Yasuhiro, Kimura Tomoki, Hashimoto Naozumi, Hasegawa Yoshinori

CLINICAL LUNG CANCER   Vol. 21 ( 3 ) page： E205 - E205   2020.5

UHRF1, a Regulator of Methylation, as a Diagnostic and Prognostic Marker for Lung Cancer Reviewed International journal

Goto Daiki, Komeda Kazuki, Uwatoko Natsuki, Nakashima Moeka, Koike Mayu, Kawai Kaho, Kodama Yuta, Miyazawa Ayako, Tanaka Ichidai, Hase Tetsunari, Morise Masahiro, Hasegawa Yoshinori, Kawabe Tsutomu, Sato Mitsuo

CANCER INVESTIGATION   Vol. 38 ( 4 ) page： 240 - 249   2020.4

Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study Reviewed International journal

Shimokawa Mototsugu, Nosaki Kaname, Seto Takashi, Ohashi Kadoaki, Morise Masahiro, Horinouchi Hidehito, Sakakibara Jun, Murakami Haruyasu, Yano Seiji, Satouchi Miyako, Matsumoto Shingo, Goto Koichi, Yoh Kiyotaka

TRIALS   Vol. 21 ( 1 )   2020.3

Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study Reviewed International journal

Okada Norio, Iwama Shintaro, Okuji Takayuki, Kobayashi Tomoko, Yasuda Yoshinori, Wada Eri, Onoue Takeshi, Goto Motomitsu, Sugiyama Mariko, Tsunekawa Taku, Takagi Hiroshi, Hagiwara Daisuke, Ito Yoshihiro, Suga Hidetaka, Banno Ryoichi, Hase Tetsunari, Morise Masahiro, Kanda Mitsuro, Yokota Kenji, Hashimoto Naozumi, Ando Masahiko, Fujimoto Yasushi, Nagino Masato, Kodera Yasuhiro, Fujishiro Mitsuhiro, Hibi Hideharu, Sone Michihiko, Kiyoi Hitoshi, Gotoh Momokazu, Ando Yuichi, Akiyama Masashi, Hasegawa Yoshinori, Arima Hiroshi

BRITISH JOURNAL OF CANCER   Vol. 122 ( 6 ) page： 771 - 777   2020.3

Risk factors for pulmonary infection after diagnostic bronchoscopy in patients with lung cancer Reviewed International journal

Shimizu Takahiro, Okachi Shotaro, Imai Naoyuki, Hase Tetsunari, Morise Masahiro, Hashimoto Naozumi, Sato Mitsuo, Hasegawa Yoshinori

NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 82 ( 1 ) page： 69 - 77   2020.2

Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer Reviewed International journal

Nakagawa Kazuhiko, Hida Toyoaki, Nokihara Hiroshi, Morise Masahiro, Azuma Koichi, Kim Young Hak, Seto Takashi, Takiguchi Yuichi, Nishio Makoto, Yoshioka Hiroshige, Kumagai Toru, Hotta Katsuyuki, Watanabe Satoshi, Goto Koichi, Satouchi Miyako, Kozuki Toshiyuki, Koyama Ryo, Mitsudomi Tetsuya, Yamamoto Nobuyuki, Asakawa Takashi, Hayashi Morihiko, Hasegawa Wakako, Tamura Tomohide

LUNG CANCER   Vol. 139   page： 195 - 199   2020.1

Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study Reviewed International journal

Kobayashi Tomoko, Iwama Shintaro, Yasuda Yoshinori, Okada Norio, Okuji Takayuki, Ito Masaaki, Onoue Takeshi, Goto Motomitsu, Sugiyama Mariko, Tsunekawa Taku, Takagi Hiroshi, Hagiwara Daisuke, Ito Yoshihiro, Suga Hidetaka, Banno Ryoichi, Yokota Kenji, Hase Tetsunari, Morise Masahiro, Hashimoto Naozumi, Ando Masahiko, Fujimoto Yasushi, Hibi Hideharu, Sone Michihiko, Ando Yuichi, Akiyama Masashi, Hasegawa Yoshinori, Arima Hiroshi

JOURNAL FOR IMMUNOTHERAPY OF CANCER   Vol. 8 ( 2 )   2020

Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors Reviewed International journal

Fukihara Jun, Sakamoto Koji, Koyama Junji, Ito Takayasu, Iwano Shingo, Morise Masahiro, Ogawa Masahiro, Kondoh Yasuhiro, Kimura Tomoki, Hashimoto Naozumi, Hasegawa Yoshinori

CLINICAL LUNG CANCER   Vol. 20 ( 6 ) page： 442 - +   2019.11

Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations Reviewed International journal

Tanaka Ichidai, Morise Masahiro, Kodama Yuta, Matsui Akira, Ozawa Naoya, Ozone Sachiko, Goto Daiki, Miyazawa Ayako, Hase Tetsunari, Hashimoto Naozumi, Sato Mitsuo, Hasegawa Yoshinori

LUNG CANCER   Vol. 127   page： 169 - 171   2019.1

eIF2 beta, a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer Reviewed International coauthorship International journal

Tanaka Ichidai, Sato Mitsuo, Kato Toshio, Goto Daiki, Kakumu Tomohiko, Miyazawa Ayako, Yogo Naoyuki, Hase Tetsunari, Morise Masahiro, Sekido Yoshitaka, Girard Luc, Minna John D., Byers Lauren A., Heymach John V., Coombes Kevin R., Kondo Masashi, Hasegawa Yoshinori

CANCER SCIENCE   Vol. 109 ( 6 ) page： 1843 - 1852   2018.6

Safety and efficacy of diagnostic flexible bronchoscopy in very old patients with lung cancer

Okachi Shotaro, Imaizumi Kazuyoshi, Imai Naoyuki, Shimizu Takahiro, Hase Tetsunari, Morise Masahiro, Hashimoto Naozumi, Sato Mitsuo, Hasegawa Yoshinori

EUROPEAN GERIATRIC MEDICINE   Vol. 9 ( 2 ) page： 255-262   2018.4

Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study Reviewed International journal

Kobayashi Tomoko, Iwama Shintaro, Yasuda Yoshinori, Okada Norio, Tsunekawa Taku, Onoue Takeshi, Takagi Hiroshi, Hagiwara Daisuke, Ito Yoshihiro, Morishita Yoshiaki, Goto Motomitsu, Suga Hidetaka, Banno Ryoichi, Yokota Kenji, Hase Tetsunari, Morise Masahiro, Hashimoto Naozumi, Ando Masahiko, Kiyoi Hitoshi, Gotoh Momokazu, Ando Yuichi, Akiyama Masashi, Hasegawa Yoshinori, Arima Hiroshi

JOURNAL OF THE ENDOCRINE SOCIETY   Vol. 2 ( 3 ) page： 241 - 251   2018.3

Prospective registry database of patients with malignant mesothelioma: directions for a future Japanese registry-based lung cancer study Reviewed International journal

Shintani Yasushi, Hasegawa Seiki, Takuwa Teruhisa, Aoe Keisuke, Kato Katsuya, Fujimoto Nobukazu, Hida Yasuhiro, Morise Masahiro, Moriya Yasumitsu, Morohoshi Takao, Okumura Meinoshin, Yoshino Ichiro

JOURNAL OF THORACIC DISEASE   Vol. 10 ( 3 ) page： 1968 - 1971   2018.3

A phase II trial of Ifosfamide combination with recommended supportive therapy for recurrent SCLC in second-line and heavily treated setting Reviewed International journal

Tanaka Ichidai, Kawada Kenji, Morise Masahiro, Hase Tetsunari, Hayashi Hiroaki, Sokai Akihiko, Fukatsu Asuki, Kondo Masashi, Nomura Fumio, Hasegawa Yoshinori

CANCER CHEMOTHERAPY AND PHARMACOLOGY   Vol. 81 ( 2 ) page： 339 - 345   2018.2

An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib. Reviewed International journal

Sato M, Matsui A, Shimoyama Y, Omote N, Morise M, Hase T, Tanaka I, Suzuki K, Hasegawa Y

Internal medicine (Tokyo, Japan)   Vol. 57 ( 23 ) page： 3429 - 3432   2018

Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer Reviewed International coauthorship International journal

Kakumu Tomohiko, Sato Mitsuo, Goto Daiki, Kato Toshio, Yogo Naoyuki, Hase Tetsunari, Morise Masahiro, Fukui Takayuki, Yokoi Kohei, Sekido Yoshitaka, Girard Luc, Minna John D., Byers Lauren A., Heymach John V., Coombes Kevin R., Kondo Masashi, Hasegawa Yoshinori

CANCER SCIENCE   Vol. 108 ( 4 ) page： 732 - 743   2017.4

Impact of mild to moderate COPD on feasibility and prognosis in non-small cell lung cancer patients who received chemotherapy. Reviewed

Omote N, Hashimoto N, Morise M, Sakamoto K, Miyazaki S, Ando A, Nakahara Y, Hasegawa Y.

Int J Chron Obstruct Pulmon Dis.   Vol. 11 ( 12 ) page： 3541-3547   2017

Impact of mild to moderate COPD on feasibility and prognosis in non-small cell lung cancer patients who received chemotherapy Reviewed International journal

Omote Norihito, Hashimoto Naozumi, Morise Masahiro, Sakamoto Koji, Miyazaki Shinichi, Ando Akira, Nakahara Yoshio, Hasegawa Yoshinori

INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE   Vol. 12   page： 3541 - 3547   2017

Factors Affecting the Diagnostic Yield of Transbronchial Biopsy Using Endobronchial Ultrasonography with a Guide Sheath in Peripheral Lung Cancer. Reviewed

Okachi S, Imai N, Imaizumi K, Iwano S, Ando M, Hase T, Aso H, Morise M, Wakahara K, Ito S, Hashimoto N, Sato M, Kondo M, Hasegawa Y

Intern Med   Vol. 55 ( 13 ) page： 1705-12   2016

The association of intravascular stromal cells with prognosis in high-grade neuroendocrine carcinoma of the lung Reviewed

Sekihara K, Hishida T, Ikemura S, Saruwatari K, Morise M, Kuwata T, Fujii S, Kojima M, Ochiai A, Funai K, Aokage K, Yoshida J, Tsuboi M, Ishii G

J Cancer Res Clin Oncol   Vol. 142 ( 5 ) page： 905-912   2016

Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy? Reviewed

Kato T, Morise M (equal first author), Ando M, Kojima E, Ogasawara T, Suzuki R, Shindoh J, Matsumoto M, Sugino Y, Ogawa M, Nozaki Y, Hase T, Kondo M, Saito H, Hasegawa Y

Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy?   Vol. 142 ( 7 ) page： 1629-40   2016

Comparison of the expression levels of molecular markers among the peripheral area and central area of primary tumor and metastatic lymph node tumor in patients with squamous cell carcinoma of the lung Reviewed

Udagawa H, Ishii G, Morise M, Umemura S, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Tsuboi M, Goto K, Ochiai A, Ohe Y

J Cancer Res Clin Oncol   Vol. 141 ( 8 ) page： 1417-25.   2015

Presence of podoplanin-positive cancer-associated fibroblasts in surgically resected primary lung adenocarcinoma predicts a shorter progression-free survival period in patients with recurrences who received platinum-based chemotherapy

Koriyama H, Ishii G, Yoh K, Neri S, Morise M, Umemura S, Matsumoto S, Niho S, Ohmatsu H, Tsuboi M, Goto K, Ochiai A

J Cancer Res Clin Oncol   Vol. 141 ( 7 ) page： 1163-70   2015

Clinicopathological significance of cancer stem-like cell markers in high-grade neuroendocrine carcinoma of the lung Reviewed

Morise M, Hishida T, Takahashi A, Yoshida J, Ohe Y, Nagai K, Ishii G

Journal of cancer research and clinical oncology     page： 2015 May 12. [Epub ahead of print]   2015

Drastic morphological and molecular differences between lymph node micrometastatic tumors and macrometastatic tumors of lung adenocarcinoma Reviewed

Aramaki N, Ishii G, Yamada E, Morise M, Aokage K, Kojima M, Hishida T, Yoshida J, Ikeda N, Tsuboi M, Ochiai A

  Vol. 142 ( 1 ) page： 37-46   2015

最新がん薬物療法学　小細胞肺癌 Invited

森瀬昌宏, 後藤功一

日本臨床 増刊号   Vol. 72 ( 2 ) page： 346-349   2014

Phase II study of erlotinib for previously treated patients with EGFR wild-type non-small-cell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System Reviewed

Morise M, Taniguchi H, Saka H, Shindoh J, Suzuki R, Kojima E, Hase T, Ando M, Kondo M, Saito H, Hasegawa Y

Mol Clin Oncol   Vol. 2 ( 6 ) page： 991-996   2014

Low-dose Irinotecan as a Second-line Chemotherapy for Recurrent Small Cell Lung Cancer Reviewed

Morise M, Niho S, Umemura S, Matsumoto S, Yoh K, Goto K, Ohmatsu H, Ohe Y

Jpn J Clin Oncol   Vol. 44 ( 9 ) page： 846-51   2014

Therapeutic Priority of the PI3K/AKT/mTOR Pathway in Small Cell Lung Cancers as Revealed by a Comprehensive Genomic Analysis Reviewed

  Vol. 9 ( 9 ) page： 1324-31   2014

環境因子と呼吸器悪性腫瘍 Invited

森瀬昌宏, 長谷川好規

呼吸と循環   Vol. 62 ( 10 ) page： 963-968   2014

特集　オンコロジーエマージェンシーと支持療法の進歩　抗がん剤による過敏反応，インフュージョンリアクション Invited

森瀬昌宏, 後藤功一

呼吸器内科   Vol. 23   page： 261-267   2013

講座　肺癌化学療法の最前線　小細胞肺癌に対する化学療法 Invited

森瀬昌宏, 後藤功一

呼吸   Vol. 32 ( 7 ) page： 631-637   2013

Nongenomic effects of fluticasone propionate and budesonide on human airway anion secretion Reviewed

Mizutani T, Morise M, Ito Y, Hibino Y, Matsuno T, Ito S, Hashimoto N, Sato M, Kondo M, Imaizumi K, Hasegawa Y

Am J Respir Cell Mol Biol   Vol. 47 ( 5 ) page： 645-51   2012

Capsaicinoids regulate airway anion transporters through Rho kinase- and cyclic AMP-dependent mechanisms Reviewed

Hibino Y, Morise M, Ito Y, Mizutani T, Matsuno T, Ito S, Hashimoto N, Sato M, Kondo M, Imaizumi K, Hasegawa Y

Am J Respir Cell Mol Biol   Vol. 45 ( 4 ) page： 684-91   2011

Heterologous regulation of anion transporters by menthol in human airway epithelial cells Reviewed

Morise M, Ito Y, Matsuno T, Hibino Y, Mizutani T, Ito S, Hashimoto N, Kondo M, Imaizumi K, Hasegawa Y

Eur J Pharmacol   Vol. 10 ( 635 ) page： 204-211   2010

Dual pathway activated by tert-butyl hydroperoxide in human airway anion secretion

Matsuno T, Ito Y, Ohashi T, Morise M, Takeda N, Shimokata K, Imaizumi K, Kume H, Hasegawa Y

J Pharmacol Exp Ther   Vol. 327 ( 2 ) page： 453-64   2008

肺病変を伴ったmulticentiric Castleman’s diseaseの一例 Reviewed

森瀬昌宏, 下元博史, 本多 豊大, 森 良雄

日本呼吸器学会誌   Vol. 41   page： 59-65   2003

胸壁原発悪性線維性組織球腫の1例 Reviewed

下元博史, 森瀬昌宏, 佐藤榮作, 山内晶司

日本胸部臨床   Vol. 62 ( 6 ) page： 561 -566   2003

レジメン別看護速習覚え書き　肺癌

森瀬昌宏, 大江裕一郎（ Role： Joint author）

メディカ出版  2012 

症例から学ぶメディカルオンコロジー　局所進行非小細胞肺癌症例

森瀬昌宏、長谷川好規（ Role： Sole author）

医薬ジャーナル社  2011.10 

コリンズスターン　胸部画像診断エッセンシャル　9章　胸膜、胸壁、横隔膜　訳

森瀬昌宏, 下方智也（ Role： Joint author）

西村書店  2011.4 

The indication of primary prevention for febrile neutropenia (FN) in elderly NSCLC patients treated with docetaxel. International conference

Morise M, Kondo M, Hasegawa Y.

2016 the Japanese Society of Medical Oncology Annual Meeting 

The efficacy and safety of re-challenge platinum plus pemtrexed combination therapy for recurrent malignant pleural mesothelioma International conference

Mariko Morishita, Masahiro Morise, Tetsunari Hase, Mitsuo Sato, Masashi Kondoh, Yoshinori Hasegawa.

16th World Conference on Lung Cancer 

Clinicopathological analysis of SRE in patients with SCLC and NSCLC International conference

Morise M, Kondo M, Hasegawa Y

Japan Society of Medical Oncology Annual meeting 2015 

The prophylactic antiemetic treatment failure in patients with lung cancer treated with CBDCA based-chemotherapy International conference

Ichikawa K, Morise M, Miyazaki M, Hase T, Kondo M, Hasegawa Y, Yamada K

Japan Society of Medical Oncology Annual meeting 2015 

Can we predict serious adverse events (SAEs) and clarify unfit population for platinum-based chemotherapy in elderly patients (over 70 years of age) with advanced Non-small cell lung cancer (NSCLC)? (CJLSG 1203 trial) International conference

Kato T, Morise M, Ando M, Kojima E, Ogasawara T, Suzuki R, Shindo J, Matsumoto M, Sugino Y, Ogawa M, Nozaki Y, Kondo M, Saito H, Hasegawa Y.

European Society of Medical Oncology Annual meeting 2014 

Clinicopathological analysis of long-term (more than 2 years) progression-free survivors treated with epidermal growth factor receptor - tyrosine kinase inhibitors (EGFR-TKIs) in patients with EGFR mutation-positive non-small cell lung cancer. International conference

Masahiro Morise, Koichi Goto, Shigeki Umemura, Shingo Matsumoto, Kiyotaka Yoh, Seiji Niho, Hironobu Ohmatsu, Kanji Nagai, Yuichiro Ohe.

15th World Conference on Lung Cancer 

Final results of EGFR mutation reanalysis and KRAS mutation screening by Scorpion ARMS method: Phase II Study of Erlotinib for EGFR wild type Non-small cell Lung Cancer Patients. Central Japan Lung Study Group (CJLSG) 0903 trial. International conference

Eiichi Maruyama, Masahiro Morise, Tetsunari Hase, Hiroyuki Taniguchi, Hideo Saka, Joe Shindoh, Ryujiro Suzuki, Eiji Kojima, Kenji Ogawa, Takuya Ikeda, Yasuhiro Nozaki, Masahiko Ando, Masashi Kondo, Hiroshi Saito, Yoshinori Hasegawa.

15th World Conference on Lung Cancer 

Phase II Study of Erlotinib for previously treated Non-small-cell Lung Cancer Patients without Epidermal Growth Factor Receptor Mutation: Central Japan Lung Study Group (CJLSG) 0903 trial International conference

Masahiro Morise, Hiroyuki Taniguchi, Hideo Saka, Joe Shindoh, Ryujiro Suzuki, Eiji Kojima, Tetsunari Hase, Masashi Kondo, Hiroshi Saito, Yoshinori Hasegawa.

高齢者非小細胞肺癌に対するプラチナ製剤併用療法に関する多施設共同後向き観察研究　（Central Japan Lung Study Group 1203試験）

田中健太郎、森瀬昌宏、安藤昌彦、加藤俊夫、小島英嗣、小笠原智彦、鈴木隆二郎、進藤丈、松本政実、杉野安輝、野﨑裕広、小川雅弘、長谷哲成、近藤征史、斉藤博、長谷川好規

第55回日本呼吸器学会学術講演会 

再発小細胞肺癌に対しアムルビシン単剤療法を施行した患者の予後因子の検討

森瀬昌宏, 麻生裕紀, 長谷哲成, 若原恵子, 伊藤理, 橋本直純, 佐藤光夫, 近藤征史, 長谷川好規

第52回日本癌治療学会総会 

EGFR-TKIにより2年以上の長期無増悪生存が得られるEGFR遺伝子変異陽性非小細胞肺癌の臨床病理学的検討

森瀬昌宏、後藤功一、梅村茂樹、松本慎吾、葉清隆、仁保誠治、大松広伸、永井完治、大江裕一郎

第54回日本肺癌学会総会 

Capsaicinoids regulate airway anion transporters through Rho kinase- and cAMP-dependent mechanisms

再発小細胞肺癌に対する60mg/m2・3週投与1週休薬法によるイリノテカン単剤療法の検討 International conference

森瀬昌宏、仁保誠治、梅村茂樹、松本慎吾、葉清隆、後藤功一、大松広伸、大江裕一郎

第53回日本肺癌学会総会 

Prognostic Factors in Recurrent Small Cell Lung Carcinoma International conference

Masahiro Morise, Takefumi Mizutani, Tomoyo Oguri, Naoyuki Imai, Tetsunari Hase, Yuichiro Shindo, Yoshihiro Inukai, Satoru Ito, Naozumi Hashimoto, Mitsuo Sato, Masashi Kondo, Yoshinori Hasegawa.

Japan Society of Medical Oncology Annual meeting 

Prospective Analysis of Efficacy and Safety of Individualized Administration of Midazolam for Sedation During Bronchoscopy International conference

Imaizumi K, Hashimoto I, Shindo Y, Imai N, Ogawa T, Morise M, Ito S, Hashimoto N, Sato M, Kondo M, Hasegawa Y

CHEST 2011 

ヒト気道上皮のイオン輸送体に対するmentholの細胞骨格を介した制御 International conference

森瀬昌宏、伊藤康、日比野佳孝、伊藤理、橋本直純、近藤征史、今泉和良、長谷川好規

アレルギー学会総会秋季大会 

IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC International coauthorship International conference

Spigel D., de Marinis F., Giaccone G., Reinmuth N., Vergnenegre A., Barrios C. H., Morise M., Felip E., Andric Z. G., Geater S., Ozguroglu M., Mocci S., McCleland M., Enquist I., Komatsubara K. M., Deng Y., Kuriki H., Wen X., Jassem J., Herbst R. S.

ANNALS OF ONCOLOGY  2019.10 

Activity of tepotinib in brain metastases (BM): Preclinical models and clinical data from patients (pts) with MET exon 14 (METex14) skipping NSCLC International coauthorship International conference

Viteri S., Mazieres J., Veillon R., Felip E., Le X., Garassino M. C., Stanton T. S., Morise M., Lee J-S., Matsumoto S., De Marinis F., Wehler T., Clark A., Friese-Hamim M., Stroh C., Bruns R., Otto G., Paik P. K.

ANNALS OF ONCOLOGY  2020.9 

Alectinib in Previously Treated RET-Rearranged Advanced Non-Small-Cell Lung Cancer: A Phase 1/2 Trial (ALL-RET) International conference

Yanagitani N., Takeuchi S., Murayama T., Yoshimura K., Imai Y., Takahara S., Kawakami T., Seto T., Hattori Y., Ohashi K., Morise M., Matsumoto S., Yoh K., Goto K., Nishio M., Yano S.

JOURNAL OF THORACIC ONCOLOGY  2019.10 

eIF2 beta, A Subunit of Translation-Initiation Factor EIF2, as a Potential Therapeutic Target for Non-Small Cell Lung Cancer International conference

Goto D., Tanaka I., Sato M., Kato T., Miyazawa A., Hase T., Morise M., Sekido Y., Girard L., Minna J., Byers L., Heymach J., Coombes K., Kondo M., Hasegawa Y.

JOURNAL OF THORACIC ONCOLOGY  2018.10 

Clinicopathological Significance of Cancer Stem-Like Cell Markers in High-Grade Neuroendocrine Carcinoma of the Lung International conference

Morise Masahiro, Hishida Tomoyuki, Takahashi Akiko, Yoshida Junji, Ohe Yuichiro, Nagai Kanji, Ishii Genichiro

JOURNAL OF THORACIC ONCOLOGY  2017.1 

Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study International coauthorship International conference

Herbst R. S., de Marinis F., Giaccone G., Reinmuth N., Vergnenegre A., Barrios C. H., Morise M., Felip E., Andric Z., Geater S., Ozguroglu M., Mocci S., McCleland M., Zou W., Enquist I., Komatsubara K., Deng Y., Kuriki H., Spigel D. R., Jassem J.

ANNALS OF ONCOLOGY  2019.12 

Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by PD-L1 immunohistochemistry (IHC) assays and blood tumour mutational burden (bTMB): IMpower110 International coauthorship International conference

Herbst R. S., De Marinis F., Giaccone G., Stahel R., Reinmuth N., Vergnenegre A., Barrios C. H., Morise M., Felip E., Andric Z., Geater S., Ozguroglu M., Mocci S., McCleland M., Zou W., Enquist I., Komatsubara K., Deng Y., Kuriki H., Spigel D., Jassem J.

SWISS MEDICAL WEEKLY  2020.11.18 

Alectinib in Previously Treated RET-Rearranged Advanced Non-Small-Cell Lung Cancer: A Phase 1/2 Trial (ALL-RET) International conference

Yanagitani N., Takeuchi S., Murayama T., Yoshimura K., Imai Y., Takahara S., Kawakami T., Seto T., Hattori Y., Ohashi K., Morise M., Matsumoto S., Yoh K., Goto K., Nishio M., Yano S.

JOURNAL OF THORACIC ONCOLOGY  2019.10 

Activity of tepotinib in brain metastases (BM): Preclinical models and clinical data from patients (pts) with MET exon 14 (METex14) skipping NSCLC International coauthorship International conference

Viteri S., Mazieres J., Veillon R., Felip E., Le X., Garassino M. C., Stanton T. S., Morise M., Lee J-S., Matsumoto S., De Marinis F., Wehler T., Clark A., Friese-Hamim M., Stroh C., Bruns R., Otto G., Paik P. K.

ANNALS OF ONCOLOGY  2020.9 

A nationwide genomic screening project for small cell lung cancer in Japan (LC-SCRUM-Japan) International conference

Daga Haruko, Umemura Shigeki, Ohe Yuichiro, Shiota Tetsuhiro, Fujita Masaki, Furuya Naoki, Tsuda Takeshi, Morise Masahiro, Matsumoto Shingo, Goto Koichi

ANNALS OF ONCOLOGY  2017.10 

Final PFS analysis and safety data from the phase III J-ALEX study of alectinib (ALC) vs. crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK plus NSCLC). International conference

Seto Takashi, Nishio Makoto, Hida Toyoaki, Nokihara Hiroshi, Morise Masahiro, Kim Young Hak, Azuma Koichi, Takiguchi Yuichi, Yoshioka Hiroshige, Kumagai Toru, Hotta Katsuyuki, Watanabe Satoshi, Goto Koichi, Satouchi Miyako, Kozuki Toshiyuki, Nakagawa Kazuhiko, Mitsudomi Tetsuya, Yamamoto Nobuyuki, Asakawa Takashi, Tamura Tomohide

JOURNAL OF CLINICAL ONCOLOGY  2019.5.20 

Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer International conference

Oi H., Yamano Y., Yokoyama T., Matsuda T., Morise M., Kataoka K., Kimura T., Kondoh Y.

ANNALS OF ONCOLOGY  2019.11 

UHRF1 as a Potential Therapeutic Target for KRAS Mutated Non-Small Cell Lung Cancer International conference

Goto D., Kizuki M., Uwatoko N., Kawai K., Koike M., Nakashima M., Miyazawa A., Tanaka I., Hase T., Morise M., Hasegawa Y., Minna J., Sato M.

JOURNAL OF THORACIC ONCOLOGY  2019.10 

The Subunit eIF2 ss of Translation- Initiation Factor EIF2 Is a Potential Therapeutic Target for Non-Small Cell Lung Cancer International conference

Sato Mitsuo, Tanaka Ichidai, Goto Daiki, Kato Toshio, Kakumu Tomohiko, Miyazawa Ayako, Yogo Naoyuki, Hase Tetsunari, Morise Masahiro, Sekido Yoshitaka, Kondo Masashi, Hasegawa Yoshinori

CANCER SCIENCE  2018.12 

Tepotinib in Patients with Advanced NSCLC with MET Exon 14 (METex14) Skipping: Overall Efficacy Results from VISION Cohort A International coauthorship International conference

Mazieres J., Paik P., Felip E., Veillon R., Sakai H., Cortot A., Viteri S., Garassino M., Van Meerbeeck J., Raskin J., Thomas M., Morise M., Cho B. C., Conte P., Bruns R., Demuth T., Schumacher K. M., Le X.

JOURNAL OF THORACIC ONCOLOGY  2021.1 

Tepotinib in patients with advanced non-small lung cancer (NSCLC) and MET exon 14-skipping mutations: Phase II data International coauthorship International conference

Sakai H., Felip E., Cortot A. B., Veillon R., Griesinger F., Patel J., Horn L., Mazieres J., De Castro Carpeno J., Morise M., Sakamoto T., Bruns R., Scheele J., Straub J., Paik P.

ANNALS OF ONCOLOGY  2018.11 

Tepotinib in patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping: Overall efficacy results from VISION cohort A International coauthorship International conference

Mazieres J., Paik P. K., Felip E., Veillon R., Sakai H., Cortot A. B., Viteri S., Garassino M. C., Van Meerbeeck J. P., Raskin J., Thomas M., Morise M., Cho B. C., Conte P., Bruns R., Demuth T., Schumacher K. M., Le X.

ANNALS OF ONCOLOGY  2020.9 

Tepotinib in NSCLC patients with METex14 mutations: interim results from the phase II VISION study International coauthorship International conference

Sakai Hiroshi, Veillon Remi, Cortot Alexis B., Felip Enriqueta, Mazieres Julien, Morise Masahiro, Sakamoto Tomohiro, Tokito Takaaki, Atagi Shinji, Kato Terufumi, Kumagai Toru, Tanaka Hiroshi, Bruns Rolf, Straub Josef, Scheele Juergen, Le Xiuning, Paik Paul K.

ANNALS OF ONCOLOGY  2019.10 

Tepotinib in NSCLC patients harboring METex14 skipping: Cohort A of phase II VISION study International conference

Park K., Felip E., Veillon R., Cortot A., Mazieres J., Sakai H., Reinmuth N., Viteri S., Chen Y-M., Han J-Y., Jang T-W., Morise M., Sakamoto T., Tokito T., Cho B. C., Bruns R., Scheele J., Straub J., Le X., Paik P. K.

ANNALS OF ONCOLOGY  2019.11 

Tepotinib in Asian patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping International coauthorship International conference

Yang J. C-H., Le X., Cho B. C., Han J-Y., Morise M., Chen Y-M., Kang J-H., Kato T., Takeoka H., Chikamori K., Sakai H., Park K., Wu Y-L., Schumacher K., Bruns R., Straub J., Paik P.

ANNALS OF ONCOLOGY  2020.11 

Tepotinib Activity in Brain Metastases (BM): Preclinical Models and Clinical Data from MET Exon 14 (METex14) Skipping NSCLC International coauthorship International conference

Viteri S., Mazieres J., Veillon R., Felip E., Le X., Garassino M., Stanton T., Morise M., Lee J. -S., Matsumoto S., De Marinis F., Wehler T., Clark A., Friese-Hamim M., Stroh C., Bruns R., Otto G., Paik P.

JOURNAL OF THORACIC ONCOLOGY  2021.1 

Short Hydration Regimen with a Modified Dose of Magnesium Supplementation for Lung Cancer Patients Receiving Cisplatin-Based Chemotherapy International conference

Hase T., Miyazaki M., Ichikawa K., Yogo N., Ozawa N., Ando M., Morise M., Sato M., Kondo M., Yamada K., Hasegawa Y.

JOURNAL OF THORACIC ONCOLOGY  2018.10 

Serum CRP Decrease Has Predictive Value for LongTerm Disease Control by PD-1/ PD-L1 Inhibitors in Patients with NSCLC International conference

Matsuzawa R., Morise M., Tanaka I., Koyama J., Kimura T., Kondoh Y., Hase T., Sakamoto K., Hashimoto N., Hasegawa Y.

JOURNAL OF THORACIC ONCOLOGY  2019.10 

Risk Factor Evaluation of Programmed Death 1 Inhibitor Related Pneumonitis in Patients with Non-Small Cell Lung Cancer International conference

Fukihara J., Sakamoto K., Iwano S., Morise M., Hashimoto N., Hasegawa Y.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE  2018 

PREDICT1: An observational study for identifying blood biomarkers associated with clinical benefit from carboplatin and pemetrexed (CbP) treatment in patients with non-squamous (NS) non-small cell lung cancer (NSCLC) (CJLSG1201). International conference

Hase Tetsunari, Yanagisawa Kiyoshi, Fukatsu Asuki, Kimura Tomoki, Kojima Eiji, Abe Takashi, Imaizumi Kazuyoshi, Horio Yoshitsugu, Oguri Tetsuya, Yamamoto Masashi, Ogasawara Tomohiko, Sugino Yasuteru, Morise Masahiro, Nakatochi Masahiro, Ando Masahiko, Kondo Masashi, Saka Hideo, Saito Hiroshi, Hasegawa Yoshinori, Takahashi Takashi

JOURNAL OF CLINICAL ONCOLOGY  2020.5.20 

Phase II study of tepotinib in NSCLC patients with METex14 mutations. International coauthorship International conference

Paik Paul K., Veillon Remi, Cortot Alexis B., Felip Enriqueta, Sakai Hiroshi, Mazieres Julien, Griesinger Frank, Horn Leora, Senellart Helene, Van Meerbeeck Jan P., de Castro Carpeno Javier, Patel Jyoti D., Garassino Marina Chiara, Morise Masahiro, Reinmuth Niels, Viteri Santiago, Tokito Takaaki, Sakamoto Tomohiro, Scheele Juergen, Le Xiuning

JOURNAL OF CLINICAL ONCOLOGY  2019.5.20 

Phase II study of gedatolisib for small-cell lung cancer (SCLC) patients (pts) with genetic alterations in PI3K/AKT/mTOR pathway based on a large-scale nationwide genomic screening network in Japan (EAGLE-PAT/LC-SCRUM-Japan). International conference

Udagawa Hibiki, Ikeda Takaya, Umemura Shigeki, Daga Haruko, Toyozawa Ryo, Harada Daijiro, Sakakibara-Konishi Jun, Morise Masahiro, Yamamoto Noboru, Takahashi Toshiaki, Kato Terufumi, Shingyoji Masato, Ushio Ryota, Hara Satoshi, Takata Saori, Nomura Shogo, Matsumoto Shingo, Niho Seiji, Sato Akihiro, Goto Koichi

JOURNAL OF CLINICAL ONCOLOGY  2020.5.20 

Phase II study of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study International conference

Shimokawa M., Nosaki K., Seto T., Ohashi K., Morise M., Fujiwara Y., Sakakibara J., Murakami H., Yano S., Satouchi M., Matsumoto S., Goto K., Yoh K.

ANNALS OF ONCOLOGY  2019.4 

IMPOWER110: INTERIM OVERALL SURVIVAL (OS) ANALYSIS OF A PHASE III STUDY OF ATEZOLIZUMAB (ATEZO) MONOTHERAPY VS PLATINUM-BASED CHEMOTHERAPY (CHEMO) AS FIRST-LINE (1L) TREATMENT IN PD-L1-SELECTED NSCLC International coauthorship International conference

Herbst Roy, De Marinis Filippo, Giaccone Giuseppe, Reinmuth Niels, Vergnenegre Alain, Barrios Carlos, Morise Masahiro, Font Enriqueta, Andric Zoran, Geater Sarayut, Ozguroglu Mustafa, Mocci Simonetta, McCleland Mark, Enquist Ida, Komatsubara Kim, Deng Yu, Kuriki Hiroshi, Wen Xiaohui, Jassem Jacek, Spigel David

JOURNAL FOR IMMUNOTHERAPY OF CANCER  2020.4 

Impower110: Interim OS Analysis of a Phase III Study Of Atezolizumab (ATEZO) vs Platinum-Based Chemotherapy (Chemo) as 1L Treatment (TX) in PD-L1-Selected NSCLC International coauthorship International conference

Reinmuth Niels, Spigel David, De Marinis Filippo, Giaccone Giuseppe, Verynenegre Alain, Barrios Carlos Henrique, Morise Masahiro, Felip Enriqueta, Andric Zoran, Geater Sarayut, Ozgueroglur Mustafa, Mocci Simonetta, Mccleland Mark, Enquist Ida, Kotnatsubara Kim, Deng Yu, Kuriki Hiroshi, Wen Xiaohui, Jassem Jacek, Herbst Roy S.

ONCOLOGY RESEARCH AND TREATMENT  2020.2 

Impact Of Mild To Moderate COPD On Prognosis And Feasibility For Chemotherapy In Patients With Lung Cancer

Omote N., Hashimoto N., Morise M., Miyazaki S., Ando A., Hasegawa Y.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE  2017 

Impact of Combined Evaluation Using Tumor Volume and Metastatic Nodal Extent in Stage III NSCLC Treated with CRT International conference

Tamiya Y., Morise M., Matsuzawa R., Tanaka I., Okada T., Iwano S., Hase T., Hashimoto N., Sato M., Itoh Y., Hasegawa Y.

JOURNAL OF THORACIC ONCOLOGY  2019.10 

Immune checkpoint inhibitor for advanced or recurrent non-small cell lung cancer patients with poor performance status International conference

Koyama Junji, Kimura Tomoki, Oi Hajime, Yamano Yasuhiko, Yokoyama Toshiki, Matsuda Toshiaki, Kataoka Kensuke, Matsuzawa Reiko, Fukihara Jun, Sakamoto Koji, Morise Masahiro, Hashimoto Naozumi, Kondoh Yasuhiro, Hasegawa Yoshinori

ANNALS OF ONCOLOGY  2019.10 

Identification of Proteosomal Catalytic Subunit PSMA6 as a Therapeutic Target for Lung Cancer through a Pooled shRNA Screen International conference

Sato M., Kakumu T., Goto D., Kato T., Yogo N., Hase T., Morise M., Fukui T., Yokoi K., Sekido Y., Girard L., Minna J., Byers L., Heymach J., Coombes K., Kondo M., Hasegawa Y.

JOURNAL OF THORACIC ONCOLOGY  2017.11 

次世代シークエンサーによる網羅的がん関連遺伝子パネル解析を用いたHER2遺伝子変異陽性の進行非小細胞肺癌に対する治療開発を目指した研究 (AMED)

2018 - 2019

革新的がん医療実用化研究事業  

岡本勇

悪性胸膜中皮腫に対する血管新生阻害剤の効果予測モデル構築に基づく新治療法確立に関する研究 (AMED)

2017.9 - 2018.3

革新的がん医療実用化研究事業 

長谷川好規

遺伝子スクリーニング基盤（LC-SCRUM-Japan）を利用した、MET遺伝子異常陽性の進行非小細胞肺癌に対する治療開発を目指した研究 (AMED)

2017.4 - 2020.3

革新的がん医療実用化研究事業  

Efficacy and safety of oral granisetron and dexamethasone for crizotinib-induced nausea and vomiting in patient with non-small cell lung cancer (NSCLC)

2015.1

Cooperative Research within Japan